LONDON (Reuters)—Europe’s top drug regulator weighed into the medicine pricing debate on Wednesday, arguing a smarter and faster pharmaceutical approval system was needed to help rein in the spiraling cost of new treatments. In exchange for speeding up the approval process, society would expect manufacturers to charge less for innovative medicines, European Medicines Agency (EMA)…
U.S. Public Health Funding on the Decline
(Reuters Health)—U.S. public health funding, which covers such things as disease prevention, cancer screenings, contraceptives and vaccines, has been steadily falling in recent years and is expected to keep going down, a recent study projects. Real, inflation-adjusted public health expenditures surged from $39 per capita in 1960 to $281 per capita in 2008, then fell…
U.S. Doctor Group Calls for Ban on Drug Advertising to Consumers
(Reuters)—The American Medical Association on Tuesday called for a ban on advertising prescription drugs and medical devices directly to consumers, saying the ads drive patients to demand expensive treatments over less costly ones that are also effective. The influential doctors’ group said the new policy reflects physicians’ concerns that marketing spending on a proliferation of…
Obama Nominee to Lead FDA Defends Drug Industry Ties
(Reuters)—President Barack Obama’s nominee to head the U.S. Food and Drug Administration defended his ties to the pharmaceutical industry on Tuesday during a Senate committee hearing that included questions on soaring drug prices. Presidential candidate Bernie Sanders was among the Democrats who grilled Dr. Robert Califf (64), who joined the FDA in January as a…
U.S. Drug Benefit Managers Clamp Down on Specialty Pharmacies
NEW YORK/LOS ANGELES (Reuters)—In recent days, the largest U.S. managers of private prescription drug benefits have cut off at least eight pharmacies that work closely with drugmakers, intensifying scrutiny of a system that helps inflate drug prices, officials at the benefit managers told Reuters. The terminations come from payers who together manage drug benefits for…
High-Spending Doctors Are Less Likely to Be Sued
NEW YORK (Reuters Health)—Providing more care than necessary may work to lower a doctor’s risk of being accused of malpractice, suggests a new U.S. study. Although the results can’t prove extra expenditures are due to defensive medicine, the researchers found that doctors in Florida who provided the most costly care between 2000 and 2009 were…
Signatures to Be Filed for California Drug Price Referendum
SACRAMENTO, Calif. (Reuters)—Backers of a referendum aimed at reducing the cost of prescription drugs in California said Wednesday that they had gathered more than enough signatures to place their measure on the November 2016 ballot in the most populous U.S. state. The measure by the AIDS Healthcare Foundation would require the state to pay no…
Don’t Bank on U.S. Drug Price Rises, Warns GSK Boss
LONDON (Reuters)—Pharmaceutical companies cannot depend on ever increasing prices in the U.S. and will need to find a new balance between incentives for innovation and access to medicines, according to the chief executive of GlaxoSmithKline. High drug prices have come under fierce political fire recently in America, the industry’s biggest and most profitable market, with…
Hospital-Owned Physician Practices Linked to Higher Prices
(Reuters Health)—Outpatient care may cost more when hospitals own the medical practices or employ the physicians, a U.S. study suggests. Hospital employment of doctors and ownership of physician practices has grown over the past decade as healthcare providers seek to curb expenses with economies of scale and deliver better coordinated treatment to patients. Research reported…
Transatlantic Divide: How U.S. Pays Three Times More for Drugs
LONDON (Reuters)—U.S. prices for the world’s 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters. The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs in America from industry critics such…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- Next Page »